This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.48% per year. These returns cover a period from January 1, 1988 through May 5, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Top Research Reports for Costco, Chubb & Cigna
by Mark Vickery
Zacks highlights strong prospects for COST, CB, and CI, with Costco's steady growth, Chubb's strategic expansion, and Cigna's solid Q1 performance amid margin pressures.
EXCPositive Net Change CBNegative Net Change CIPositive Net Change COSTNegative Net Change MDLZPositive Net Change SELFNegative Net Change NHTCPositive Net Change NETNegative Net Change
consumer-discretionary insurance medical reit retail
Regeneron Initial Data on Multiple Myeloma Drug Encouraging
by Zacks Equity Research
REGN posts strong early data for linvoseltamab combos in relapsed/refractory multiple myeloma, with ORRs up to 90% and high complete response rates.
REGNNegative Net Change NVSPositive Net Change RHHBYPositive Net Change PFEPositive Net Change
biotechnology medical pharmaceuticals
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
by Zacks Equity Research
CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.
CNMDNegative Net Change CVSPositive Net Change CORPositive Net Change WGSPositive Net Change
medical medical-devices
Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication
by Zacks Equity Research
FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.
REGNNegative Net Change NVSPositive Net Change RHHBYPositive Net Change PFEPositive Net Change
medical pharmaceuticals
CI's Unit Unveils Offering to Expand Access to GLP-1 Medications
by Zacks Equity Research
Cigna's Evernorth business caps GLP-1 drug copays at $200 or less, aiming to boost affordability for patients and cut costs for health plan sponsors.
CIPositive Net Change CRMDPositive Net Change ITGRPositive Net Change EHCPositive Net Change
medical
2 S&P 500 Stocks to Buy Now On the Dip for Huge Upside
by Benjamin Rains
Diving into two beaten-down S&P 500 stocks--Thermo Fisher Scientific and Lululemon--to consider buying now for huge upside.
TMONegative Net Change LULUNegative Net Change
consumer-discretionary medical
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
by Sundeep Ganoria
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
NVONegative Net Change LLYNegative Net Change CRBPNegative Net Change SKYENegative Net Change
biotechs marijuana medical pharmaceuticals
UnitedHealth vs. Elevance: Which Healthcare Stock Has More Upside?
by Kaibalya Pravo Dey
ELV outpaces UNH with stronger earnings, leaner costs and clearer guidance, making it the healthcare stock with more upside right now.
UNHNegative Net Change ELVNegative Net Change
healthcare hmo insurance medical
RVTY Stock Falls Despite the Latest Launch of Automated Instrument
by Zacks Equity Research
Revvity unveils IDS i20, a fully automated immunodiagnostics platform designed to enhance lab efficiency and expand specialty testing.
CORPositive Net Change ITGRPositive Net Change HIMSPositive Net Change RVTYNegative Net Change
medical medical-devices
PacBio Stock Slips Despite New China Distribution Deal With Haorui
by Zacks Equity Research
PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.
ANGOPositive Net Change CVSPositive Net Change PACBNegative Net Change ITGRPositive Net Change
medical medical-devices
Reasons to Retain TransMedics Stock in Your Portfolio for Now
by Zacks Equity Research
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
ANGOPositive Net Change CVSPositive Net Change ITGRPositive Net Change TMDXPositive Net Change
medical medical-devices
Do Options Traders Know Something About InMode Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to InMode stock based on the movements in the options market lately.
INMDNegative Net Change
medical medical-devices
Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases
by Zacks Equity Research
BAYRY's Eylea 8 mg gets CHMP nod in EU, promising 6-month dosing for nAMD and DME with strong 3-year efficacy and safety data.
REGNNegative Net Change BAYRYPositive Net Change HALOPositive Net Change AMRNPositive Net Change
biotechnology biotechs medical pharmaceuticals
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort
by Zacks Equity Research
Exelixis' zanzalintinib/Opdivo combo shows superior efficacy for treating kidney cancer in an expansion cohort of the phase Ib/II STELLAR-002 study.
BMYNegative Net Change BAYRYPositive Net Change EXELNegative Net Change AMRNPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
4 Stocks Trading Near 52-Week High With Room to Rise Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like DB, HRTG, PAHC and TGI are seeing price strength and the momentum is likely to continue.
TGIPositive Net Change DBNegative Net Change PAHCPositive Net Change HRTGPositive Net Change
aerospace finance medical
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
by Zacks Equity Research
EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.
EWPositive Net Change PBHPositive Net Change PAHCPositive Net Change HIMSPositive Net Change
medical medical-devices
The Zacks Analyst Blog Highlights Eli Lilly, GE Aerospace and Amgen
by Zacks Equity Research
Zacks highlights LLY, GE, and AMGN as top picks, citing strong demand, product pipelines, and defense tailwinds despite some pricing and margin pressures.
GEPositive Net Change LLYNegative Net Change AMGNNegative Net Change
aerospace medical pharmaceuticals
QGEN Stock Might Gain Following New Partnership With ID Solutions
by Zacks Equity Research
QGEN teams up with ID Solutions to boost QIAcuity's reach in oncology dPCR assays, aiming to strengthen its cancer research leadership.
ANGOPositive Net Change DXCMNegative Net Change QGENNegative Net Change STENegative Net Change
medical
Do Options Traders Know Something About RxSight Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to RXST stock based on the movements in the options market lately.
RXSTNegative Net Change
medical
Brookdale Shares Down 4.9% Despite Q1 Earnings Meeting Estimates
by Zacks Equity Research
BKD continues to witness growth in revenue per available unit (RevPAR). It increases its EBITDA range for 2025.
BKDNegative Net Change CNCNegative Net Change EHCPositive Net Change WGSPositive Net Change
earnings finance medical
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
by Zacks Equity Research
RMD gains on strong mask sales and digital health growth, but faces macro headwinds and fierce competition.
ANGOPositive Net Change RMDNegative Net Change CVSPositive Net Change ITGRPositive Net Change
medical
FDA Approves GSK's Nucala for Expanded Use in COPD
by Zacks Equity Research
GSK's Nucala wins FDA nod for COPD with eosinophilic phenotype, marking its fifth indication and strengthening its respiratory portfolio.
REGNNegative Net Change SNYNegative Net Change GSKNegative Net Change VRNAPositive Net Change
biotechs medical pharmaceuticals
Best Value Stocks to Buy for May 23rd
by Zacks Equity Research
PAHC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 23, 2025.
PAHCPositive Net Change
medical
Top Analyst Reports for Eli Lilly, GE Aerospace & Amgen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace (GE) and Amgen Inc. (AMGN).
GEPositive Net Change LLYNegative Net Change AMGNNegative Net Change WMPositive Net Change TEAMNegative Net Change WPMPositive Net Change
aerospace medical pharmaceuticals
Abbott vs. Medtronic: Which Dividend-Paying MedTech Stock is Better?
by Urmimala Biswas
With both MDT & ABT focusing on their core strengths, the stage is set for a compelling comparison. Let's see which stock is poised for greater upside.
ABTNegative Net Change MDTNegative Net Change
dividend dividend-stocks dividend-yield earnings-outlook earnings-report healthcare medical medical-devices